In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pangaea

Executive Summary

Pangaea is designing therapeutics to suppress autoimmune recognition, with technology based on the discovery of a universal blocking normal self peptide.

You may also be interested in...



QUOTED. 5 June 2020. US FDA.

A new document from the US FDA details acceptable substitutions for COVID-19 testing components that may be difficult to come by. See what the regulatory agency said about it here.

CIR Expert Panel Rebranded Ahead Of June Virtual Meeting

The renamed Expert Panel for Cosmetic Ingredient Safety has its own website now, which includes the conflict of interest statement its members are expected to sign. The panel will meet virtually 8-9 June to consider a raft of ingredient reports in various stages of development at Cosmetic Ingredient Review.

Korea Seeks Two-Track Strategy For COVID-19 Drugs, Vaccines

As a recent increase in silent virus spreaders in metropolitan areas raises concerns, South Korea unveils policy measures to support the development of COVID-19 drugs and vaccines, as well as to secure imports of such products if necessary.

Topics

UsernamePublicRestriction

Register

ID1131170

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel